GO
Loading...

Mylan Inc

More

  • TEL AVIV, Dec 11- Teva Pharmaceutical Industries forecast 2015 revenue below analysts' expectations, due to adverse foreign exchange moves and generic competition for its best-selling multiple sclerosis treatment Copaxone. There are two teams developing cheaper generic forms of Copaxone: one involving Novartis AG's Sandoz Inc and Momenta...

  • NEW YORK/ WINNIPEG, Dec 9- Valeant Pharmaceuticals International Inc is abandoning its growth-by-acquisitions strategy for the time being to try to reduce debt, boost its stock price and one day return to its traditional deal-making in a stronger position, people familiar with the matter told Reuters. Speculation about Valeant's next takeover target has...

  • NEW YORK/ WINNIPEG, Dec 9- Valeant Pharmaceuticals International Inc is abandoning its growth-by-acquisitions strategy for the time being to try to reduce debt, boost its stock price and one day return to its traditional deal-making in a stronger position, people familiar with the matter told Reuters. Speculation about Valeant's next takeover target has...

  • Hedge funds playing buy-and-hold, and losing Monday, 24 Nov 2014 | 10:54 AM ET
    Pedestrians pass in front of an Apple store in New York.

    Hedge funds aren't changing their stock holdings much despite poor performance compared with the broader stock market.

  • Taxes, multinational firms & Luxembourg—revealed Thursday, 6 Nov 2014 | 5:50 PM ET
    Luxembourg old city

    Luxembourg has come under fire for operating as a tax haven, but it's always been hard to prove how companies use it to cut their tax bills—until now.

  • Nov 6- Hospira Inc reported a quarterly profit that handily beat analysts' estimates as the company raised prices and sold more of its injectable drugs. Hospira's shares rose as much as 9.2 percent to a more than three-year high of $57.99 on Thursday. Hospira challenged the decision but lost the case.

  • Early Movers: HLT, SBUX, C, LNKD, GPRO & more Friday, 31 Oct 2014 | 8:10 AM ET

    Some of the names on the move ahead of the open.

  • Midday movers: Deere, GrubHub, Lazard, Pfizer & more Thursday, 23 Oct 2014 | 12:50 PM ET

    Some of Thursday's midday movers:

  • U.S. court upholds patents on Pfizer's cancer drug Thursday, 23 Oct 2014 | 8:57 AM ET

    Oct 23- A U.S. district court ruled in favor of Pfizer Inc in a patent lawsuit it filed against Mylan Inc alleging patent infringement on its cancer drug, Sutent, Pfizer said. Pfizer filed the lawsuit in June 2010 after Mylan attempted to market a generic version of Sutent, patented until 2021.. The case is Pfizer Inc v.

  • Oct 22- Drugmakers Abbott Laboratories and Mylan Inc on Wednesday declined to explain in detail why they changed the terms of a $5.3 billion deal in which Mylan will buy part of Abbott's overseas generics business and reincorporate for tax purposes in the Netherlands. Windau said many investors had feared the new Treasury rules might derail the deal, and they...

  • Oct 22- Abbott Laboratories and Mylan Inc said on Wednesday they would go ahead with their $5.3 billion deal in which Mylan will buy part of Abbott's overseas generics business and set up headquarters in the Netherlands, but they tweaked the terms of the transaction. Treasury on Sept. 22 made changes to the corporate tax rules that govern such "inversion" merger...

  • Abbott says third-quarter sales match forecasts Wednesday, 22 Oct 2014 | 8:11 AM ET

    Oct 22- Abbott Laboratories said its third-quarter sales were in line with Wall Street forecasts and that it had slightly changed the terms of a deal to sell generic drugs to Mylan Inc.. Abbott on Wednesday said sales from continuing and discontinued operations rose 4.7 percent to $5.6 billion in the third quarter. That included generic medicines, now...

  • WASHINGTON, Oct 15- The U.S. Supreme Court on Wednesday appeared closely divided as it weighed Teva Pharmaceutical Industries Ltd's high-profile fight with generic drug manufacturers over patent protections for Copaxone, its top-selling multiple sclerosis drug. Israel- based Teva is battling to protect a key patent for the $4- billion- a-year MS drug that is...

  • WASHINGTON, Oct 15- The U.S. Supreme Court on Wednesday appeared closely divided as it weighed Teva Pharmaceutical Industries Ltd's high-profile fight with generic drug manufacturers over patent protections for Copaxone, its top-selling multiple sclerosis drug. The $4- billion- a-year drug accounts for 50 percent of Teva profits, and the patent fight is one...

  • Oct 15- Major U.S. drugmaker AbbVie Inc said on Wednesday it was reconsidering a $55 billion bid for Ireland's Shire Plc, marking a setback for "inversion" deals in which U.S. companies reincorporate abroad to cut tax costs. Steris Corp said on Monday it has offered to buy Britain's Synergy Health Plc for about $1.9 billion in a deal that would shift Steris' tax...

  • WASHINGTON, Oct 15- The U.S. Supreme Court on Wednesday is set to wade into Teva Pharmaceutical Industries Ltd's fight over patent protections for Copaxone, its top-selling multiple sclerosis drug, in one of the most important business cases of the justices' new term. There are two teams developing cheaper generic forms of Copaxone: one involving Novartis AG's...

  • Oct 9- Impax Laboratories Inc said it was on the hunt for further deals- and would consider a so-called "tax inversion" transaction- after its acquisition of two privately held Pennsylvania drugmakers for $700 million. Impax's shares jumped as much as 17 percent to $17.85 in morning trading on the Nasdaq on Thursday. The acquisition of Lineage Therapeutics Inc...

  • Oct 8- If Actavis Plc proceeds with a purchase of Botox maker Allergan Inc for potentially more than $60 billion, it will represent the biggest bet yet by one of the traditional generic drugmakers on the upside of expanding branded medicine holdings. Reuters reported on Tuesday that Actavis plans to approach Allergan about a potential merger, providing an...

  • Former Yahoo executive nixes idea of AOL deal Tuesday, 7 Oct 2014 | 9:07 AM ET
    Tim Armstrong, CEO of AOL and Marissa Mayer, CEO of Yahoo Inc.

    Former Yahoo President Sue Decker says a merger with AOL would make little sense.

  • Midday Movers: Media General, Noble, Yodlee & More Friday, 3 Oct 2014 | 12:10 PM ET

    Take a look at some of Friday's midday movers.